Trial Profile
A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythematosus
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Rituximab (Primary) ; Methylprednisolone; Mycophenolate mofetil; Prednisolone
- Indications Systemic lupus erythematosus
- Focus Proof of concept; Therapeutic Use
- Acronyms SynBioSe-2
- 05 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Dec 2023.
- 12 Nov 2022 Trial design published in the Trials.
- 04 Jun 2022 Results of a meta-analysis by pooling individual patient MBC flow cytometry data from 1245 patients with SLE from from four randomised clinical trials (NCT00071487, NCT00410384, NCT01632241 and NCT01649765) and extensive B-cell subset phenotyping was performed prospectively by employing high-sensitivity flow cytometry (NCT03312907 and NCT03747159) presented at the 23rd Annual Congress of the European League Against Rheumatism